Article: CSL Marks 40 Years in the Influenza Vaccine Market.

A Leading Provider of Vaccine in the Southern Hemisphere and Europe

PARKVILLE, Australia -- CSL Limited today celebrated its 40th year as a leading manufacturer of the influenza (flu) vaccine. The company's vaccine, Fluvax([R]), is a Thiomersal-free influenza vaccine that is approved for use in adults and children in Australia and New Zealand. This vaccine is known as Afluria[TM], Enzira[TM], Nilgrip[TM], and X-Flu[TM] in 17 different countries, including the US and European markets. Additionally, CSL supplies the antigen used to manufacture the flu vaccine in 24 countries.

CSL's prominence in the influenza vaccine market has grown dramatically over the ...

Related newspaper, magazine, and journal articles:

 
 
Newsweek Harper's Magazine The Washington Post Chicago Tribune Crain's Chicago Business PRNewswire Pediatric News The Nation Advertising Age The Economist (US) A FREE trial gives you access to over 80 million articles! Access over 6,500 publications with a FREE trial!